RxDoctor Payments Data

Veronica Guel-Valdivia, MD

Family Medicine · Victoria, TXNPI 1821056102

Payments from drug & device makers

$12,174in general payments, 2019–2025

Across 732 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • AbbVie$1K
  • Pfizer$1K
  • Lilly USA, LLC$818
  • Boehringer Ingelheim$723
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$12,08599%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,174 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$49,402
Medicare patients
88
Services billed
874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$89,401
MounjaroTirzepatide64$71,157
FarxigaDapagliflozin Propanediol68$66,085
JardianceEmpagliflozin45$50,097
MyrbetriqMirabegron34$23,741
TrulicityDulaglutide20$18,894
EliquisApixaban15$14,888
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$9,586
JanuviaSitagliptin Phosphate11$9,001
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$6,592
Varenicline Tartrate15$4,075
Gabapentin122$3,134
Atorvastatin Calcium249$1,916
Simvastatin249$1,629
Levothyroxine Sodium191$1,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$818$90,05184 claims
Novo NordiskOzempic$2,010$89,40162 claims
AstraZenecaFarxiga$1,820$66,08568 claims
Boehringer IngelheimJardiance$723$50,09745 claims
Astellas Pharma US IncMyrbetriq$217$23,74134 claims
PfizerEliquis$1,066$14,88815 claims
MerckJanuvia$229$9,00111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Victoria

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →